{
    "nct_id": "NCT03070340",
    "official_title": "Comparison of Breast Magnetic Resonance Imaging (MRI) and Contrast Enhanced Mammography (CEDM) to Evaluate Residual Disease Extent After Neoadjuvant Therapy (NAT)",
    "inclusion_criteria": "* Any woman who has completed or is nearing completion of neoadjuvant therapy for breast cancer and is scheduled for a post-NAT breast MRI and mammogram\n* Surgery (mastectomy or BCT) planned within 60 days of the MRI\nHealthy volunteers allowed\nMust be FEMALE",
    "exclusion_criteria": "* Women who have a contraindication to the intravenous use of iodinated contrast agent (i.e., allergy to iodinated contrast or severely impaired renal function with a creatinine level > 1.3 or eGFR â‰¥45)\n* Known allergic reaction to gadolinium; patient may be eligible if the referring physician determines that the MRI is medically necessary and if the patient is willing to undergo pre-medication for contrast allergy\n* Pregnant women\n* Male patients\n* Presence of non MR compatible metallic objects or metallic objects that, in the opinion of the radiologist, would make MRI a contraindication\n* Known or suspected renal impairment. Requirements for GFR prior to MRI as determined by local site standard practice\n* Women who have already had their standard of care post-NAT mammogram and/or breast MRI",
    "miscellaneous_criteria": ""
}